VCYT Q1 2022 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+84.7% YoY

Gross Profit

$44M65.0% margin

Operating Income

-$15M-22.5% margin

Net Income

-$14M-21.3% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$11M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$88M

Stockholders' Equity

$1.1B

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$37M	+84.7%
Gross Profit	$44M	$24M	+81.4%
Operating Income	-$15M	-$45M	+66.4%
Net Income	-$14M	-$42M	+65.5%

Revenue Segments

Biopharmaceutical And Other

$9M75%

Product

$3M25%